Annual CFO
-$63.30 M
-$19.92 M-45.91%
31 December 2023
Summary:
Lyra Therapeutics annual cash flow from operations is currently -$63.30 million, with the most recent change of -$19.92 million (-45.91%) on 31 December 2023. During the last 3 years, it has fallen by -$42.16 million (-199.41%). LYRA annual CFO is now -853.37% below its all-time high of -$6.64 million, reached on 31 December 2018.LYRA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$16.22 M
+$3.76 M+18.81%
30 September 2024
Summary:
Lyra Therapeutics quarterly cash flow from operations is currently -$16.22 million, with the most recent change of +$3.76 million (+18.81%) on 30 September 2024. Over the past year, it has dropped by -$2.11 million (-14.94%). LYRA quarterly CFO is now -579.83% below its all-time high of $3.38 million, reached on 30 June 2021.LYRA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$77.72 M
-$2.11 M-2.79%
30 September 2024
Summary:
Lyra Therapeutics TTM cash flow from operations is currently -$77.72 million, with the most recent change of -$2.11 million (-2.79%) on 30 September 2024. Over the past year, it has dropped by -$21.31 million (-37.77%). LYRA TTM CFO is now -2486.26% below its all-time high of -$3.00 million, reached on 31 March 2019.LYRA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LYRA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -45.9% | -14.9% | -37.8% |
| 3 y3 years | -199.4% | -57.3% | -281.1% |
| 5 y5 years | -853.4% | -323.9% | -690.1% |
LYRA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -199.4% | at low | -91.5% | +27.8% | -281.1% | at low |
| 5 y | 5 years | -853.4% | at low | -579.8% | +27.8% | -690.1% | at low |
| alltime | all time | -853.4% | at low | -579.8% | +27.8% | -2486.3% | at low |
Lyra Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$16.22 M(-18.8%) | -$77.72 M(+2.8%) |
| June 2024 | - | -$19.98 M(-11.0%) | -$75.61 M(+8.2%) |
| Mar 2024 | - | -$22.45 M(+17.8%) | -$69.91 M(+10.4%) |
| Dec 2023 | -$63.30 M(+45.9%) | -$19.06 M(+35.0%) | -$63.30 M(+12.2%) |
| Sept 2023 | - | -$14.11 M(-1.2%) | -$56.41 M(+6.1%) |
| June 2023 | - | -$14.28 M(-9.9%) | -$53.14 M(+12.3%) |
| Mar 2023 | - | -$15.85 M(+30.3%) | -$47.33 M(+9.1%) |
| Dec 2022 | -$43.38 M(+68.0%) | -$12.16 M(+12.2%) | -$43.38 M(+2.0%) |
| Sept 2022 | - | -$10.85 M(+28.1%) | -$42.52 M(+1.3%) |
| June 2022 | - | -$8.47 M(-28.9%) | -$41.99 M(+39.3%) |
| Mar 2022 | - | -$11.90 M(+5.4%) | -$30.14 M(+16.7%) |
| Dec 2021 | -$25.82 M | -$11.30 M(+9.5%) | -$25.82 M(+26.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$10.31 M(-405.1%) | -$20.39 M(+47.2%) |
| June 2021 | - | $3.38 M(-144.5%) | -$13.86 M(-43.9%) |
| Mar 2021 | - | -$7.59 M(+29.3%) | -$24.72 M(+16.9%) |
| Dec 2020 | -$21.14 M(+53.7%) | -$5.87 M(+55.2%) | -$21.14 M(+10.2%) |
| Sept 2020 | - | -$3.78 M(-49.5%) | -$19.19 M(-0.2%) |
| June 2020 | - | -$7.48 M(+86.2%) | -$19.24 M(+30.3%) |
| Mar 2020 | - | -$4.02 M(+2.5%) | -$14.77 M(+7.4%) |
| Dec 2019 | -$13.75 M(+107.1%) | -$3.92 M(+2.4%) | -$13.75 M(+39.8%) |
| Sept 2019 | - | -$3.83 M(+27.4%) | -$9.84 M(+63.7%) |
| June 2019 | - | -$3.00 M(-0.0%) | -$6.01 M(+100.0%) |
| Mar 2019 | - | -$3.00 M | -$3.00 M |
| Dec 2018 | -$6.64 M | - | - |
FAQ
- What is Lyra Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Lyra Therapeutics?
- What is Lyra Therapeutics annual CFO year-on-year change?
- What is Lyra Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Lyra Therapeutics?
- What is Lyra Therapeutics quarterly CFO year-on-year change?
- What is Lyra Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Lyra Therapeutics?
- What is Lyra Therapeutics TTM CFO year-on-year change?
What is Lyra Therapeutics annual cash flow from operations?
The current annual CFO of LYRA is -$63.30 M
What is the all time high annual CFO for Lyra Therapeutics?
Lyra Therapeutics all-time high annual cash flow from operations is -$6.64 M
What is Lyra Therapeutics annual CFO year-on-year change?
Over the past year, LYRA annual cash flow from operations has changed by -$19.92 M (-45.91%)
What is Lyra Therapeutics quarterly cash flow from operations?
The current quarterly CFO of LYRA is -$16.22 M
What is the all time high quarterly CFO for Lyra Therapeutics?
Lyra Therapeutics all-time high quarterly cash flow from operations is $3.38 M
What is Lyra Therapeutics quarterly CFO year-on-year change?
Over the past year, LYRA quarterly cash flow from operations has changed by -$2.11 M (-14.94%)
What is Lyra Therapeutics TTM cash flow from operations?
The current TTM CFO of LYRA is -$77.72 M
What is the all time high TTM CFO for Lyra Therapeutics?
Lyra Therapeutics all-time high TTM cash flow from operations is -$3.00 M
What is Lyra Therapeutics TTM CFO year-on-year change?
Over the past year, LYRA TTM cash flow from operations has changed by -$21.31 M (-37.77%)